Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$27,000.00
In vivo chimeric antigen receptor (CAR)-macrophages for solid tumour immunotherapy using lipid nanoparticle delivery systems
EF 2024-25
Résumé
Cancer is the leading cause of death in Canada, but current treatment options often fail to cure the disease. A promising new form of treatment is cancer immunotherapy, which boosts the immune system ability to fight cancer. One type of immunotherapy, called chimeric antigen receptor (CAR) therapy, involves modifying immune cells to express a CAR, allowing them to better recognize and attack cancer. CAR therapy using T cells (CAR-T therapy) has been very effective for treating blood cancers, but it struggles to work against solid tumours, which make up over 90% of cancers. To overcome this challenge, researchers are using another type of immune cell called a macrophage to make CAR macrophage (CAR-M) therapy. Macrophages are a promising candidate because they are abundant in solid tumours and have many anti-cancer functions. Early studies of CAR-M therapies have shown promise, but the process of collecting, modifying, and re-infusing these cells into patients is costly, complex, and time-consuming. Furthermore, CARs were originally designed for T cells, meaning they need significant improvements to function well in macrophages.This project aims to simplify and improve upon current CAR-M therapies by delivering CAR instructions (CAR messenger RNA) directly to macrophages at the tumour site. We will achieve this using lipid nanoparticles (LNPs), which are particles that can carry genetic material safely into cells. We will design CARs tailored specifically for macrophages, block signals that suppress their activity, and test this strategy in pre-clinical cancer models. If successful, this innovative strategy could make CAR therapy more affordable, efficient, and accessible for patients with solid tumours, offering a transformative new option in cancer care.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
530063
Name
Koshyk Alexandra
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
In vivo chimeric antigen receptor (CAR)-macrophages for solid tumour immunotherapy using lipid nanoparticle delivery systems
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Chimeric Antigen Receptor (Car); Colorectal; Immune Cell Engineering; Immuotherapy; Lipid Nanoparticles; Lung); Mouse Models Of Cancer; Mrna Therapeutics; Ovarian; Solid Tumours (Breast; Tumour Associated Macrophages (Tams); Tumour Microenvironment (Tme)
Abstract
Cancer is the leading cause of death in Canada, but current treatment options often fail to cure the disease. A promising new form of treatment is cancer immunotherapy, which boosts the immune system ability to fight cancer. One type of immunotherapy, called chimeric antigen receptor (CAR) therapy, involves modifying immune cells to express a CAR, allowing them to better recognize and attack cancer. CAR therapy using T cells (CAR-T therapy) has been very effective for treating blood cancers, but it struggles to work against solid tumours, which make up over 90% of cancers. To overcome this challenge, researchers are using another type of immune cell called a macrophage to make CAR macrophage (CAR-M) therapy. Macrophages are a promising candidate because they are abundant in solid tumours and have many anti-cancer functions. Early studies of CAR-M therapies have shown promise, but the process of collecting, modifying, and re-infusing these cells into patients is costly, complex, and time-consuming. Furthermore, CARs were originally designed for T cells, meaning they need significant improvements to function well in macrophages.This project aims to simplify and improve upon current CAR-M therapies by delivering CAR instructions (CAR messenger RNA) directly to macrophages at the tumour site. We will achieve this using lipid nanoparticles (LNPs), which are particles that can carry genetic material safely into cells. We will design CARs tailored specifically for macrophages, block signals that suppress their activity, and test this strategy in pre-clinical cancer models. If successful, this innovative strategy could make CAR therapy more affordable, efficient, and accessible for patients with solid tumours, offering a transformative new option in cancer care.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Koshyk, Alexandra
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~